Dr. Tagawa compares the use of PSMA-targeted antibodies to other treatment approaches such as radioligand therapy.
RLT
Advertisement
Latest News
Dr. Kishan reviews current evidence supporting the use of PSMA RLT in patients with oligometastatic disease.
177Lu vipivotide tetraxetan is the only PSMA-targeted agent to significantly improve rPFS with a tolerable safety profile.
Dr. Morris discusses trials and rationale behind using PSMA therapy earlier in prostate cancer treatment.
Dr. Hofman outlines promising PSMA combination therapies and emerging trials aiming to improve prostate cancer outcomes.
Dr. Calais provides an overview of this year's PSMA and Beyond conference agenda.
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Expert Interviews
Prostate Cancer Knowledge Hubs
Curated clinical content on prostate cancer types, therapies, and technologies
Conference Coverage
Dr. Canes discusses the formation of the WellPrept delivery platform and how it aims to boost patient education.
Mohummad Siddiqui, MD, discusses his work with the Commission on Cancer and their development on standards of care.
John P. Sfakianos, MD, discusses the history and use of ctDNA in the GU oncology field.
Dr. Sandoval chats with David Ambinder, MD, on the upstaging of cT1b and cT2 tumors to pT3a.
Maximizing Benefits and Minimizing Harm: Reviewing AUA Guidelines on Prostate Cancer Early Detection
Dr. Salami explains how updated guideline approaches shared decision-making in higher-risk groups.Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.